Background and Aims: Despite the screening of blood donors, blood transfusion represents an ideal port of entry for blood-borne infection. Blood-borne pathogen transmission has been a concern since the earliest days of transfusion. The blood product of platelet (PLT) concentrates is still faced with the risk of bacterial and viral contaminations. Pathogen inactivation technologies offer a proac...

background and aims: despite the screening of blood donors, blood transfusion represents an ideal port of entry for blood-borne infection. blood-borne pathogen transmission has been a concern since the earliest days of transfusion. the blood product of platelet (plt) concentrates is still faced with the risk of bacterial and viral contaminations. pathogen inactivation technologies offer a proac...

In the last 10 years three technologies capable of inactivating pathogens in platelet concentrates have been authorized in Europe although only one based on the addition of amotosalen and illumination with ultraviolet A (UVA) light, has been approved by the National Agency for the Safety of Medicines and Health Products (ANSM). An intense debate exists about the implementation of pathogen inact...

Pathogen inactivation systems are in use in many European countries as routine procedures. However, a pathogen inactivation system for erythrocytes is currently not available. Although significant improvements have been made to decrease the incidence of transfusion-transmitted infections, risks remain for infectious disease agents specific to red blood cell concentrates, such as parasitic infec...

Submit Manuscript | http://medcraveonline.com have proven to be effective against numerous bacteria, viruses, and parasites. Two main systems have emerged to treat platelet concentrates: treatment with psoralen ultraviolet A (UVA) light and treatment with riboflavin (vitamin B2) plus ultraviolet B (UVB) light, both targeting the nucleic acids of pathogens. The ability of the Mirasol PRT system ...

PURPOSE OF REVIEW In the past 20 years, several pathogen inactivation technologies have been developed to be applied to blood components. This review is intended to summarize the data currently available about the technologies and the clinical use of products inactivated by those techniques. RECENT FINDINGS Technologies for inactivating pathogens in plasma and platelets are available, and are...

Background and Aims: Fresh Frozen Plasma (FFP) is one of blood components. The risk of transmission of viruses from blood components regardless selection of blood donors and screening donated blood still remains. There are several methods for viral inactivation. In this study methylene blue (MB) photo inactivation process was used for inactivating viruses. Materials and Methods: In this study M...